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Overview
• Anatomy and pathology 
• Epidemiology
• Screening
• Management
• Waiver

General Population
• Lifetime prevalence 10% male, 5% female
 Increasing incidence (20 - 74 y.o.)
• 3.7% to 4.6% of commercial aviation pilots2
1. Hall, P. (2009) Nephrolithiasis: Treatment, causes and prevention, Clev Clin J Med, 76(10):583-591
2. Hyams, E., et al. (2011) The incidence of urolithiasis among commercial aviation pilots, J Urol, 186:914-916.
Mineralized Renal Material (MRM)
• Small areas of calcification found incidentally
• Of uncertain significance
• We need to characterize MRM
 How common?
 Do they turn into stones or disappear with time?
 Is spaceflight a risk factor for clinical stones?
Screening Needs
• Management of MRM/stone has varied widely
• Unknown how many astronauts have MRM
• Understanding is important for future missions
Screening Needs
• Periodic screening  Annual exams
• Low or no radiation  Ultrasound
• Standardized methodology   Ultrasound review panel
• Standardized management   A clinical practice guideline
When to Screen?
Ultrasound Benefits
• Low cost
• No radiation
• Easy to do
• Easy to repeat
• Minimal time commitment for astronauts



Natural History
Size (mm) Stone Free Progression Intervention
<= 5 28% 40.4% 5.3%
5 - 10 4.8% 52.4% 9.5%
>= 10 0% 71.4% 14.3%
Koh et al. (2011), Outcomes of long-term follow-up of patients with conservative management of asymptomatic renal caliculi, BJU Int, 109:622-625.
Spontaneous Passage vs. Stone Size
Ueno et al. (1977), Relation of spontaneous passage of ureteral calculi to size, Urology, 10(6):544-546
The Sweet Spot!
Enhanced U/S Protocol
1. Echogenic  seen from 2 or more angles
2. Shadowing  opaque to ultrasound
3. Twinkling  twinkling in Doppler mode
4. Dispersion  spectral frequency dispersion
5. Measurable  >3 mm
6. Location  parenchymal, papillary or collecting system
Enhanced U/S Protocol
• Standardized and systematic screening
• Multiple scanning positions
• Multiple probe views
• Various ultrasound modes
Clinical Practice Guideline
• Annual ultrasound for all active astronauts
• Use of specialized ultrasound protocol
• Suspicion for stone  Low-dose, high resolution CT
• Stone by CT  Flexible Ureteroscopy preferred
• Mission assignment affects treatment method
• Potential waivers for very small, stable MRM
US Navy Standards
• Waivers given for...
 calcium oxalate, calcium phosphate, uric acid and 
struvite; 
 retained stones in the renal parenchyma; 
 recurrent stones > 12 months apart.
• Medical evaluation & urology consult required
US Navy Standards
• Waivers NOT given for...
 recurrent stones within one year 
 cysteine stones 
 hypercalcuria
 stones retained in the collecting system



Where we are…
• All active astronauts have been screened
 4 were post-flight
• Seven renal panel meetings done
• Prelim results to NASA-AMB Summer 2017
Ureteral Stone Size and Time to Passage
Treatment During a Mission?
Miller and Kane (1999), Time to stone passage for observed ureteral calculi: A guide for patient education, J. Urology, 162:688-691.
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Sensitivity (%) Specificity (%) Dose (mSv)
Ultrasound
Average 2.6 mm (1 – 9 mm, SD 1.15 ), n = 51 pts, 114 stones [17]
Shadowing alone 65 (PPV 90) - 0
Twinkling alone 81 (PPV 94) - 0
Shadowing + Twinkle 88 (PPV 96) - 0
Average 3.9 mm ( 1-20 mm), n = 105 pts, 65 stones, CT as reference [18]
Shadowing alone 48 (PPV 81) 99 0
Shadowing + Twinkle 55 (PPV 67) 99 0
X-Ray
KUB 45 - 58 69 - 77 0.7
IVP 85 90 3
CT
Low-dose, non-con. 97 95 3
Non-contrast 95 – 98 96 - 98 10
MRI
93 - 100 95 - 100 0
